Phase-Dependent Treatment of Delayed Sleep Phase Syndrome with Melatonin

Mundey, Kavita; Benloucif, Susan; Harsanyi, Krisztina; Dubocovich, Margarita L.; Zee, Phyllis C.

doi:10.1093/sleep/28.10.1271

Cited by 193 publications

(134 citation statements)

References 34 publications

Supporting

Mentioning

128

Contrasting

Unclassified

Order By: Relevance

“…In the first use of melatonin in patients with DSPS, it was found that when administered 5 h before sleep onset for a period of 4 weeks, melatonin (5 mg) advanced sleep onset and wake times compared with placebo (Dahlitz et al, 1991), which was later confirmed by Nagte gaal et al (1998) and Mundey et al (2005), and is most effective in DSPS patients with shorter habitual sleep time and later clinical onset (Kamei et al, 2000).…”

Section: Implications For the Treatment Of Insomnia And Circadian mentioning

confidence: 86%

What Keeps Us Awake?—the Role of Clocks and Hourglasses, Light, and Melatonin

Cajochen

Chellappa

Schmidt

2010

International Review of Neurobiology

View full text Add to dashboard Cite

Section: Implications For the Treatment Of Insomnia And Circadian mentioning

confidence: 86%

What Keeps Us Awake?—the Role of Clocks and Hourglasses, Light, and Melatonin

Cajochen

Chellappa

Schmidt

2010

International Review of Neurobiology

View full text Add to dashboard Cite

“…Melatonin is widely used to treat various sleep disorders [119][120][121][122][123][124][125][126][127][128][129][130], including disorders associated with delayed phase sleep syndrome [119][120][121], periodic sleep disorders in blind patients [122][123][124][125] and sleep and behavioral disorders in children with severe brain damage [126][127][128][129]. In a randomized double-blind, placebo-controlled study [130], melatonin was shown to improve sleep efficiency and sleep latency [130] in cystic fibrosis (CF) patients, a chronic progressive disorder characterized by repeated episodes of respiratory distress and sleep disturbances [130].…”

Section: Role Of Melatonin In Maintaining and Restoring Human Healthmentioning

confidence: 99%

Melatonin: A pleiotropic molecule regulating inflammation

Radogna

Diederich

Ghibelli

2010

Biochemical Pharmacology

308

247

View full text Add to dashboard Cite

Melatonin is a neurohormone produced by the pineal gland that regulates sleep and circadian functions. Melatonin also regulates inflammatory and immune processes acting as both an activator and inhibitor of these responses. Melatonin demonstrates endocrine, but also paracrine and autocrine effects in the leukocyte compartment: on one side, leukocytes respond to melatonin in a circadian fashion; on the other side, leukocytes are able to synthesize melatonin by themselves.With its endocrine and paracrine effects, melatonin differentially modulates pro-inflammatory enzymes, controls production of inflammatory mediators such as cytokines and leukotrienes and regulates the lifespan of leukocytes by interfering with apoptotic processes. Moreover, its potent anti-oxidant ability allows scavenging of oxidative stress in the inflamed tissues. The interesting timing of pro-and anti-inflammatory effects, such as those affecting lipoxygenase activity, suggests that melatonin might promote early phases of inflammation on one hand and contribute to its attenuation on the other hand, in order to avoid complications of chronic inflammation. This review aims at giving a comprehensive overview of the various inflammatory pathways regulated by this pleiotropic hormone.

show abstract

“…[29] Evening administration of melatonin (0.3-5mg) between 7pm and 8pm shifts circadian rhythms to an earlier time. [29,30] …”

Section: Delayed Sleep Phase Syndrome (Dsps)mentioning

confidence: 99%

“…Participants unsuitable (n= 5) [26][27][28][29][30] Insufficient data for analysis (n= 2) [31,32] Inappropriate method and data collection (n= 4) [33][34][35][36] No clear comparison group (n= 4) [37][38][39][40] Number of studies included in review (n=13) [41][42][43][44][45][46][47][48][49][50][51][52] Publications handpicked (screening reference list) (n= 2) …”

mentioning

confidence: 99%

Evidence for the efficacy of melatonin in the treatment of primary adult sleep disorders

Auld

Maschauer

Morrison

et al. 2017

Sleep Medicine Reviews

335

142

View full text Add to dashboard Cite

Melatonin is a physiological hormone involved in sleep timing and is currently used exogenously in the treatment of primary and secondary sleep disorders with empirical evidence of efficacy, but very little evidence from randomised, controlled studies. The aim of this meta-analysis was to assess the evidence base for the therapeutic effects of exogenous melatonin in treating primary sleep disorders. An electronic literature review search of MEDLINE (1950-present) EMBASE (1980- present), PsycINFO (1987- present), and SCOPUS (1990- present), along with a hand-searching of key journals was performed in July 2013 and then again in May 2015. This identified all studies that compared the effect of exogenous melatonin and placebo in patients with primary insomnia, delayed sleep phase syndrome, Non 24- hour sleep wake syndrome in people who are blind, and REM-Behaviour Disorder. Meta-analyses were performed to determine the effect of magnitude in studies of melatonin in improving sleep. A total of 5030 studies were identified; of these citations, 13 were included for review based on the inclusion criteria of being: double or single-blind, randomised and controlled. Results from the meta-analyses showed the most convincing evidence for exogenous melatonin use was in reducing sleep onset latency in primary insomnia (p=0.002), delayed sleep phase syndrome (p<0.0001), and regulating the sleepwake patterns in blind patients compared with placebo. These findings highlight the potential importance of melatonin in treating certain first degree sleep disorders. The development of large-scale, randomised, controlled trials is recommended to provide further evidence for therapeutic use of melatonin in a variety of sleep difficulties

show abstract

Phase-Dependent Treatment of Delayed Sleep Phase Syndrome with Melatonin

Abstract: These results indicate that melatonin advances the circadian clock and sleep in patients with DSPS in a phase-dependent manner. This is the first study that reports a relationship between timing of melatonin administration and phase changes in patients with DSPS.

Cited by 193 publications

References 34 publications

What Keeps Us Awake?—the Role of Clocks and Hourglasses, Light, and Melatonin

What Keeps Us Awake?—the Role of Clocks and Hourglasses, Light, and Melatonin

Melatonin: A pleiotropic molecule regulating inflammation

Evidence for the efficacy of melatonin in the treatment of primary adult sleep disorders

Contact Info

Product

Resources

About